King's Research Portal

Link to publication record in King's Research Portal

Citation for published version (APA):

Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal

Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 09. Jan. 2020
OUTCOME MEASUREMENT IN FUNCTIONAL NEUROLOGICAL DISORDER
– A SYSTEMATIC REVIEW AND RECOMMENDATIONS


1. Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
2. University of the Witwatersrand, Donald Gordon Medical Centre, Johannesburg, South Africa
3. Neuroscience Research Center, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran; Jefferson Comprehensive Epilepsy Center, Department of Research, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
4. Department of Neurology, University Hospital Bern and University of Bern, Bern, Switzerland
5. Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
6. Erasmus University Medical Centre; Donders Institute for Brain, Cognition and Behaviour; Department of Neurology; Nijmegen, the Netherlands
7. School of Health Sciences, University of Manchester and Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK
8. Department of Clinical Neurosciences, School of Molecular and Clinical Medicine, University of Edinburgh, Western General Hospital, Crewe Rd, Edinburgh, UK
9. Institute of Mental Health, Division of Psychiatry, Faculty of Brain Sciences, University College London, London, UK
10. Neuroscience Research Centre, Institute of Molecular and Clinical Sciences, St George’s University of London, London, UK
11. Department of Psychiatry, Georgetown University, Washington DC, USA
12. Gardner Family Center for Parkinson’s disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA
13. Department of Neurology, Hôpital Avicenne, Assisteante Publique Hôpitaux de Paris (APHP), Paris
14. Human Motor Control Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA
15. Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
17. Department of Psychiatry, University of Melbourne, Austin Health, Melbourne, Victoria, Australia
18. The Children’s Hospital at Westmead, Discipline of Psychiatry and Child and Adolescent Health, University of Sydney Medical School, Sydney, Australia
19. Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
20. Departments of Psychiatry and Neurology, Rhode Island Hospital, Brown Medical School, Providence, RI, USA
21. The Edmond J Safra Program in Parkinson’s Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University of Toronto, Canada
22. Mater Centre for Neurosciences, Brisbane, Australia
23. Department of Neurology, Stony Brook University School of Medicine, Stony Brook, New York, USA
24. FND Hope International
25. Northeast Regional Epilepsy Group, New York, USA
26. Therapy Services, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom
27. Departments of Neurology and Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
28. Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany
29. Academic Neurology Unit, University of Sheffield, Royal Hallamshire Hospital, Glossop Road, Sheffield, United Kingdom
30. Departments of Neurology and Psychiatry and Behavioral Sciences, Emory Centre for Ethics, Emory University, Atlanta, Georgia, USA
31. Department of Neurology, Medical University of Graz, Graz, Austria
32. Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague Czech Republic
33. Department of Neurological Sciences, Rush University Medical Center, Chicago, USA
34. Department of Neurology, University Medical Centre Groningen, University of Groningen, the Netherlands
35. Department of Neuroscience, Biomedicine, and Movement, University of Verona, Verona, Italy

*corresponding author

Address for correspondence:
Dr. Timothy R Nicholson
Section of Cognitive Neuropsychiatry, PO68, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, London, UK, SE5 8AF. Email: timothy.nicholson@kcl.ac.uk. Telephone: ++44 207 848 5136
Key words: functional neurological; functional movement disorder; conversion disorder; psychogenic non-epileptic seizures; outcome; measurement; treatment; dissociative
ABSTRACT

Objective: We aimed to identify existing outcome measures for functional neurological disorder (FND), to inform the development of recommendations and guide future research on FND outcomes.

Method: A systematic review was conducted to identify existing FND-specific outcome measures and the most common measurement domains and measures in previous treatment studies. Searches of Embase, Medline, and PsycINFO were conducted between January 1965 and June 2019. The findings were discussed during two international meetings of the FND-Core Outcome Measures group.

Results: Five FND-specific measures were identified - three clinician-rated and two patient-rated, but their measurement properties have not been rigorously evaluated. No single measure was identified for use across the range of FND symptoms in adults. Across randomised controlled trials (k=40) and observational treatment studies (k=40), outcome measures most often assessed core FND symptom change. Other domains measured commonly were additional physical and psychological symptoms, life impact (i.e., quality of life, disability, general functioning) and health economics/cost-utility (e.g., healthcare resource utilisation, quality adjusted life years).

Conclusions: There are few well-validated FND-specific outcome measures. Thus, at present we recommend that existing outcome measures, known to be reliable, valid and responsive in FND or closely related populations, are used to capture key outcome domains. Increased consistency in outcome measurement will facilitate comparison of treatment effects across FND symptom types and treatment modalities. Future work needs to more rigorously validate outcome measures used in this population.
INTRODUCTION

Functional neurological disorder (FND, conversion disorder) is defined by motor and sensory symptoms (e.g., tremor, dystonia, limb weakness, numbness, seizures), that demonstrate clinical features incompatible with other neurological/medical diagnoses and that are associated with significant distress and functional impairment.[1-3] Until recently, there were few controlled treatment trials and little research effort into outcome measurement in FND. However, there has been a marked increase in the number and quality of intervention studies, so it is now critical to optimise outcome measures for this population, to facilitate comparison of the effectiveness and efficacy of different treatment modalities for specific FND symptoms.

FND has features that make decisions regarding outcome measurement particularly complex.[4, 5] These include heterogeneity and variability of symptoms, and the marked influence of attention, beliefs and expectations.[6-8] Discrepancy between objective measures and patients' subjective experiences of symptoms can also be a prominent feature.[9] These aspects of FND potentially make objective “snap-shot” measures (e.g., clinician-rated scales, objective performance tests) less reliable and valid. They also suggest that patient-rated outcomes may be particularly meaningful in this population.

A wide range of additional physical symptoms (e.g., fatigue, pain, sleep disturbance, gastrointestinal, urological problems) are common in people with FND, typically associated with reduced quality of life and greater disability.[10, 11] More generally, elevated physical symptom burden is associated with significant disability, role impairments, and high healthcare utilisation.[12, 13] Many individuals with FND report significant psychological symptoms/comorbidity (e.g., anxiety, depression, dissociation), potentially unhelpful coping behaviours and illness beliefs, and altered emotional processing, which are associated with symptom severity, poorer outcomes and diminished quality of life.[10, 11, 14-23] These factors, therefore, may be particularly relevant to psychosocial outcomes in FND.[24, 25]

There is clearly a wide range of outcome domains relevant to FND and a key challenge is to determine which are most important to capture. In evidence-based medicine, there has been an increasing emphasis on consistency in outcome measurement and the Core Outcome Measures in Effectiveness Trials (COMET, http://www.comet-initiative.org/)
initiative facilitates the development of core outcome measure sets across a range of physical and mental health disorders. The COMET collaboration recommends five key outcome domains, including core physiological/clinical symptoms, life impact (i.e., quality of life, functioning or participation, subjective health perception), resource use (health, social), adverse events and mortality. Another initiative, supported by the National Institutes of Health, involves development of “common data elements”, which currently includes core measures for neurological disorders (https://www.nlm.nih.gov/cde/summary_table_1.html).

An important step towards developing a core outcome measure set is to review measures currently used in outcome studies,[26] but there has been no previous review of outcome measures in FND. We aimed to systematically review the currently available FND-specific outcome measures and identify those measures used most frequently in FND intervention studies to date. We sought to review the outcome domains and measures used in FND treatment research and their quality, not to evaluate the treatments, outcome data, or methodologies used. Finally, we aimed to integrate these findings with conclusions derived during two international expert consensus meetings of the FND - Core Outcome Measures group (FND-COM) (http://www.comet-initiative.org/studies/details/951), with the aim of developing recommendations for outcome measurement in future studies.

**METHOD**

The systematic review was conducted in two parts to identify:

1. Publications describing existing FND-specific outcome measures.
2. Randomised controlled trials and prospective intervention studies in FND.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed.[27]

**Search strategy**

PubMed (Medline), Embase, and PsycINFO were searched for both parts of the review. Trial registry websites (e.g., clinicaltrials.gov, ISRTCN.com) were also searched to identify intervention studies. The search terms are detailed in Box 2. The terms were searched in the abstract, keyword and title fields, mapped to MeSH headings. Reference lists were
searched manually for additional sources. Members of the FND-COM group were consulted for additional studies.

**Box 1. Search terms**

*Primary terms:* ‘conversion disorder’ OR ‘psychogenic’ OR ‘non-epileptic’ OR ‘hysteri*’ OR ‘functional neurological’ OR ‘functional movement’ OR ‘functional motor’  
Combined with AND:  
**Part 1:** ‘outcome*’ OR ‘measurement instrument’ OR ‘assessment’ OR ‘scale*’ OR ‘outcome measure*’ OR ‘questionnaire’  
**Part 2:** ‘trial’ OR ‘treatment*’ OR ‘intervention’ OR ‘treatment outcome*’ OR ‘random*ed’ OR ‘therap*’.

**Eligibility criteria**

Articles written in English and published in peer-reviewed journals between January 1965 and June 2019 were included. We included registered in progress trials, for part two. Articles referring to core sensorimotor FND symptoms (including seizures) were included, whilst those referring to other less common symptoms (i.e., speech and swallowing, cognitive) were excluded.[5]

For part one, we included articles describing the psychometric evaluation of an outcome measure explicitly for FND. Instruments designed for diagnosis of FND were excluded as these are not designed to measure change in FND symptoms over time. Measures assessing symptoms across bodily systems (i.e., not exclusively neurological) and/or those validated in patients with mixed physical symptoms were excluded.

For part two, studies were eligible if they prospectively measured outcomes of a specified intervention in patients with FND. Studies were excluded if the target samples included: individuals with psychiatric diagnoses without FND, or individuals with FND as a secondary or uncertain diagnosis. Case reports, case series and retrospective designs were excluded.
Data extraction and management

Initial screening of the titles and abstracts was conducted by one author (SPick), to exclude those not meeting basic eligibility criteria (i.e., duplicates, not FND). The remaining titles, abstracts and/or full texts were screened independently by the lead author (SPick) and a second independent rater (TN, SPopkirov, RK, ABW). Disparities were resolved by discussion or by a third independent rater.

In part one, the following were extracted: (1) lead author, (2) publication date, (3) name of instrument, (4) type of instrument (e.g., self-report questionnaire, clinical evaluation), (5) content of measure (6) validation sample, (7) measurement properties. For part two, data extracted were: (1) lead author, (2) publication date, (3) geographical location, (4) nature of intervention(s), (5) design (e.g., parallel, cross-over), (6) details of blinding (i.e., participants, intervention deliverer), (7) FND symptoms, (8) sample size, (9) timescale, (10) outcome measures, (11) measurement properties. The specific measurement properties (validity, reliability, responsiveness) that were systematically extracted (where available) are defined in Supplementary File 1.[28-31]

FND-COM group consensus meetings

The findings of the reviews were discussed at two international consensus meetings (September 2017, Edinburgh, UK; September 2018, Atlanta, US) involving 43 members from 12 countries, all with expertise in FND treatment or outcome research. The members represented a range of relevant health professions (neurology, (neuro)psychiatry, (neuro)psychology, physiotherapy, occupational therapy) and patient representation.

RESULTS

Existing FND-specific outcome measures

Five articles were eligible (Appendix 1 for PRISMA diagram), which are summarised in Table 1. Three articles described clinician-rated scales, two assessing functional movement disorder (FMD) symptoms: Psychogenic Movement Disorder Rating Scale (PMDRS);[32] Simplified Functional Movement Disorder Rating Scale (S-FMDRS)[33] and one clinician-rated measure for functional (i.e., psychogenic non-epileptic/dissociative) seizures.[34] Two patient-rated measures assessed a range of FND symptoms in children (Conversion Disorder Scale, CDS and CDS-Revised).[35, 36] There was no single outcome measure for
use across FND symptom subtypes in adults and none designed specifically for functional weakness/paralysis or sensory symptoms. The measurement properties of the scales are outlined in Supplementary File 2 and summarised below.

Validity
The content validity of the measures has not been confirmed according to established standards.[27, 29] Only two studies referred to consultation with independent experts during scale development [35, 36] and none reported consultation with patients. Regarding construct validity, exploratory factor analysis was conducted for both patient-reported measures.[35, 36] The CDS had three underlying factors (disability, pain, seizures) and the CDS-R five factors (swallowing and speech, motor symptoms, sensory symptoms, weakness and fatigue, mixed symptoms).

Criterion validity for new measures of FND symptoms is difficult to assess, due to a lack of validated gold standards. However, moderate-strong correlations ($r>0.3$) with measures of similar or related constructs were noted for some scales, suggesting acceptable convergent validity.[32-34, 36] The CDS and CDS-R also differentiated FND patients from healthy controls.[35, 36]

Reliability
Inter-rater reliability (IRR) statistics for the clinician-rated scales were generally in an acceptable range (coefficients $>0.8$ for total scores), except for the seizure rating scale, which had slightly lower IRR (several coefficients $<0.7$).[34] The internal consistency of the patient-rated measures was satisfactory to good (Cronbach’s alpha values $>0.8$).[35, 36]

Responsiveness
The PMDRS detected a significant change in patients’ scores between pre- and post-intervention.[32] The S-FMDRS also displayed good sensitivity to change, with a large effect size (Cohen’s $d=0.79$) between post-treatment scores in an intervention group compared to controls.[33] Data on responsiveness were not reported for the other measures.
Limitations

Whilst the studies indicated some sound measurement properties of these scales, there were limitations to the psychometric evaluations conducted, according to the recommended guidelines.[28, 30, 31] None of the measures were evaluated in more than one study by independent research teams, although additional data on the measurement properties of the PMDRS have been provided in subsequent intervention studies. Validity data were variable and often incomplete, most importantly for content/face validity. No study included confirmatory factor analysis or Item Response Theory and Rasch analyses to assess construct validity.[37] Similarly, none of the measures were validated cross-culturally and there was limited evidence relating to ecological validity. Sample sizes were relatively small for validations (i.e., 120 or less) and a-priori sample size calculation or justification was omitted, except for one study which reported a large effect size (Cohen’s $d=0.79$) for comparison of control and intervention groups.[33] Only three studies included data from control groups.[33, 35, 36] Bias was potentially present in most samples due to recruitment within specialist healthcare clinics and/or stringent inclusion criteria. Whilst all studies presented at least one appropriate measure of reliability, there were several omissions across studies and data were generally incomplete. For example, none of the articles provided statistics on discriminant or test-retest reliability.
<table>
<thead>
<tr>
<th>Study details</th>
<th>Measure</th>
<th>Description of measure</th>
</tr>
</thead>
</table>
| **Cianci 2011 (Italy)** [34] | Rating scale for functional ‘psychogenic non-epileptic’ seizures (clinician-rated) | Motor phenomena (tremor/oscillation, tonic, clonic/jerking, hypermotor/agitation, atonic/akinetic, automatisms)  
 Associated features (incontinence, tongue-biting, drooling, eye closure, hyperventilation, lament/crying)  
 Responsiveness  
 13 body regions  
 Ratings: present/absent, severity, duration, global severity by phenomenon  
 Total phenomenology, Total associated features, Total seizure scores |
 Functions (gait, speech)  
 14 body regions  
 Ratings: present/absent, severity, duration, global severity & incapacitation by phenomenon / function (0-4 Likert)  
 Total phenomenology, Total function, Total PMD score |
| **Ijaz 2017 (Pakistan)** [36] | Conversion Disorder Scale – Revised (CDS-R) (patient-rated) | 40 items (phenomena): five factors identified (swallowing/speech, motor, sensory, weakness/fatigue, mixed)  
 Ratings: 0-2 (not at all, sometimes, most of the time) for each item  
 CDS-R Total scores (clinical cut-off score – 19) |
| **Nielsen 2017a (UK)** [33] | Simplified Functional Movement Disorders Rating Scale (S-FMDRS) (clinician-rated) | Seven body regions  
 Two functions (speech, gait)  
 Ratings: presence/absence of abnormal movement, severity, duration (0-3 Likert)  
 Total S-FMDRS score |
| **Sarfraz & Ijaz 2014 (Pakistan)** [35] | Conversion Disorder Scale (CDS) (patient-rated) | 19 items (phenomena): three factors (disability, pain, seizures) |
Outcome domains and measures in existing FND treatment studies

Randomised controlled trials
Forty RCTs were identified (31=published, 9=ongoing or unpublished) (Appendix 2 for PRISMA diagram). Supplementary Files 3 and 4 detail the study designs and outcome measures adopted. Table 2 summarises the primary outcome measures in these RCTs across FND symptom subtypes.[38-45] Most RCTs focused on FND symptom change as the primary outcome measure (k=26). The most consistent primary outcome measure was functional seizure frequency; however, studies differed in how this was operationalised (e.g., weekly or monthly seizure counts) and there was no single standardised way of recording the seizures (e.g., patient seizure logs, clinical records). For FMD, the most common approach was a structured clinician-rated scale (e.g., PMDRS), which can include standardised video protocols assessed by blind raters. Patient-rated symptom severity was often the primary outcome for functional limb weakness or mixed symptoms. The Clinical Global Impression–Improvement (CGI-I) scale[46] was used as the primary outcome measure in five studies (clinician-rated=2; patient-rated=2; unspecified=1). At least one of the CGI scales (improvement, severity) was included as a primary or secondary outcome in 13 studies.

Ten RCTs included a measure of additional physical symptoms, with the Patient Health Questionnaire-15 (PHQ-15) [47] (k=3) and Symptom Checklist-90 (SCL-90)[48] somatic subscale (k=3) used in several studies. Twenty-eight RCTs included a measure of psychological symptoms (primary or secondary), most commonly depression and/or anxiety. Patient-rated measures included the Hospital Anxiety and Depression Scale (HADS, k=9),[49] Beck Depression Inventory (BDI or BDI-II, k=7),[50] and the Beck Anxiety Inventory (BAI, k=5).[51] The Hamilton Rating Scale for Depression (HAM-D, k=8)[52] and Anxiety (HAM-A, k=4)[53] were commonly used clinician-rated measures. Psychological dissociation (e.g., depersonalisation, derealisation, amnesia) was measured with the Dissociative Experiences Scale [54] in six trials.

Life impact was assessed in most studies. The Short Form Health Survey scales (SF-12=3; SF-36=1),[55, 56] were often included to measure health-related quality of life and/or disability. The Quality of Life in Epilepsy (QoLIE, k=6) scales (originally devised for epilepsy studies) were often used for patients with seizures.[57, 58] Disability was assessed
specifically in 16 studies; however, whilst most studies used clinician-rated scales, there was little consistency in the scales adopted. Measures of general (i.e., social, occupational) functioning were included in 12 studies, most often with the Work and Social Adjustment Scale (WSAS, k=6) [59] or Global Assessment of Functioning (GAF, k=5). [60]

Table 2: Primary outcome measures used across RCTs for FND subgroups

<table>
<thead>
<tr>
<th>FND symptoms</th>
<th>Primary outcome measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizures (k=15)</td>
<td><strong>Core symptoms</strong></td>
</tr>
<tr>
<td></td>
<td>• Seizure frequency/occurrence (k=11) [38-45, S1, S2] [Fobian NCT02801136]</td>
</tr>
<tr>
<td></td>
<td><strong>Life impact</strong></td>
</tr>
<tr>
<td></td>
<td>• SF-36/QoLIE-31 (k=1) [Hingray NCT02311829]</td>
</tr>
<tr>
<td></td>
<td>• WSAS (k=1) [45]</td>
</tr>
<tr>
<td></td>
<td><strong>Other</strong></td>
</tr>
<tr>
<td></td>
<td>• Treatment adherence / HCU (k=3) [S3, S4] [Schommer NCT03329703]</td>
</tr>
<tr>
<td>Movement disorder (k=7)</td>
<td><strong>Core symptoms</strong></td>
</tr>
<tr>
<td></td>
<td>• PMDRS (k=4) or other FMD clinician-rating scale (k=1) [S5-S9]</td>
</tr>
<tr>
<td></td>
<td>• CGI-I (clinician) (k=1) [S10]</td>
</tr>
<tr>
<td></td>
<td><strong>Other</strong></td>
</tr>
<tr>
<td></td>
<td>Unspecified (k=1) [S11]</td>
</tr>
<tr>
<td>Paralysis/weakness (k=4)</td>
<td><strong>Core symptoms</strong></td>
</tr>
<tr>
<td></td>
<td>• Subjective symptom severity ratings (k=1) [S12] or CGI-I (patient) (k=1) [Nicholson ISRCTN51225587]</td>
</tr>
<tr>
<td></td>
<td>• Clinician-rated symptom severity (Chastan NCT01352910)</td>
</tr>
<tr>
<td></td>
<td>• Dynamometry (k=1) [S13]</td>
</tr>
<tr>
<td></td>
<td><strong>Life impact</strong></td>
</tr>
<tr>
<td></td>
<td>Disability (SF-12; MRS; k=1) [S12]</td>
</tr>
<tr>
<td>Mixed motor symptoms (k=4)</td>
<td><strong>Core symptoms</strong></td>
</tr>
<tr>
<td></td>
<td>• CGI-I (k=1) [Koning-Tijssen NCT02589886]</td>
</tr>
<tr>
<td></td>
<td><strong>Life impact</strong></td>
</tr>
<tr>
<td></td>
<td>• SF-36 Physical Functioning scale (k=1) [S14]</td>
</tr>
<tr>
<td></td>
<td><strong>Other</strong></td>
</tr>
<tr>
<td></td>
<td>• Unspecified (k=1) [S15]</td>
</tr>
<tr>
<td>Other mixed symptoms (k=10)</td>
<td><strong>Core symptoms</strong></td>
</tr>
<tr>
<td></td>
<td>• Clinician-rated symptom severity (k=3) [S16-S18]</td>
</tr>
<tr>
<td></td>
<td>• CGI-I (k=2; l=clinician; l=patient) [S19, S20]</td>
</tr>
<tr>
<td></td>
<td>• SDQ-20 (k=1) [S19]</td>
</tr>
<tr>
<td></td>
<td>• Recovery (unspecified, k=1) [S21]</td>
</tr>
<tr>
<td></td>
<td><strong>Life impact</strong></td>
</tr>
<tr>
<td></td>
<td>• SF-36 (k=1) [S22]</td>
</tr>
<tr>
<td></td>
<td>• MRS (k=1) [S19]</td>
</tr>
<tr>
<td></td>
<td><strong>Other</strong></td>
</tr>
<tr>
<td></td>
<td>• Treatment adherence /HCU (k=1) [Bullock NCT02764476]</td>
</tr>
<tr>
<td></td>
<td>• Interoception / attention tasks (k=1) [S23]</td>
</tr>
</tbody>
</table>

**Key:** CGI-I=Clinical Global Impression-Improvement; FMD=Functional Movement Disorder; HCU=Healthcare Utilisation; k=number of studies; MRS=Modified Rankin Scale; NeuroQoL=Quality of Life in Neurological Disorders; PMDRS=Psychogenic Movement Disorder Rating Scale; QoLIE-31=Quality of Life in Epilepsy-31; SF-12/36=Short Form Health Survey – 12/36 item; SDQ-20=Somatoform Dissociation Questionnaire-20 item; WSAS=Work and Social Adjustment Scale
Data for health economic/cost-utility analyses were also obtained in many trials. For example, healthcare resource utilisation was monitored in a notable proportion (k=15). Four studies used a validated measure (Client Services Receipt Inventory, CSRI).[S24] A few studies provided data on quality adjusted life years (QALYs) using the EQ-5D-5L.[S25]

Ten studies assessed illness perceptions or symptom attributions, often using study-specific questions or variants of the Illness Perception Questionnaire (IPQ, k=5).[S26-S28] Adverse events were reported in 11 trials.

Prospective cohort observational studies

Forty prospective observational treatment studies were identified (34=published, 6=ongoing/unpublished) (Appendix 2, Supplementary File 5). The pattern of outcome measures was very similar to the RCTs. The most common outcome domain was core symptom change (k=33). Patient-rated functional seizure frequency was measured often (k=18) and clinician-rated scales were used to assess FMD symptoms (e.g., PMDRS k=5; SFMDRS k=2) (k=11). Self-reported symptom severity was assessed in nine studies, often using the CGI-I scale (k=5). Clinician-rated CGI scales were used in a small proportion of studies (k=3).

Additional physical (k=6) and psychological (k=21) symptoms were commonly assessed. The PHQ-15 was the most frequently used measure of additional physical symptoms (k=4). Common measures of psychological symptoms included the HADS (k=5), the BAI, BDI (k=8), the HAM-D (k=5) and/or the HAM-A (k=3).

In terms of life impact, quality of life and/or disability were measured in 19 studies, with the SF-36 being the most consistently adopted measure (k=11). Thirteen studies included measures of general functioning, including the WSAS (k=4) and GAF (k=3). A proportion of studies (k=7) monitored healthcare resource utilisation, or included other measures yielding data for health economic analyses. Illness beliefs were assessed in eight studies, again with the IPQ (or revised versions) in the majority (k=5). Three studies reported adverse events.
Measurement properties of outcome measures used in FND intervention studies

The review identified several outcome domains and measures often included in FND treatment research (Table 3). Available psychometric data detailing the measurement properties of these measures were extracted (Supplementary File 6).

Table 3: Common outcome domains & measures in FND intervention studies

<table>
<thead>
<tr>
<th>Outcome domain</th>
<th>Commonly used measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Core symptoms</td>
<td>CGI-I: patient-rated=9; clinician-rated=7; both=4</td>
</tr>
<tr>
<td></td>
<td>Seizure frequency/remission=30</td>
</tr>
<tr>
<td></td>
<td>PMDRS=10</td>
</tr>
<tr>
<td>Other physical symptoms</td>
<td>PHQ-15/extended PHQ-15*=7</td>
</tr>
<tr>
<td></td>
<td>SCL-90 Somatic symptom scale=6</td>
</tr>
<tr>
<td>Psychological symptoms</td>
<td>Depression: BDI/BDI-II=12; HAM-D=13</td>
</tr>
<tr>
<td></td>
<td>Anxiety: BAI=8; HAM-A=7</td>
</tr>
<tr>
<td></td>
<td>Depression &amp; anxiety: HADS=14</td>
</tr>
<tr>
<td>Life impact: quality of life / disability / general functioning</td>
<td>SF-36=22; SF-12=3</td>
</tr>
<tr>
<td></td>
<td>QoLIE-31=7; QoLIE-10=2</td>
</tr>
<tr>
<td></td>
<td>WSAS=10</td>
</tr>
<tr>
<td></td>
<td>GAF=8</td>
</tr>
<tr>
<td>Health economics/cost-utility</td>
<td>Healthcare resource utilisation=20 (CSRI=4)</td>
</tr>
<tr>
<td></td>
<td>QALYs (SF-36/EQ-5D-SL)=3</td>
</tr>
<tr>
<td>Illness beliefs / attributions</td>
<td>IPQ / modified IPQ=10</td>
</tr>
</tbody>
</table>

Key: BAI=Beck Anxiety Inventory; BDI=Beck Depression Inventory; CGI=Clinical Global Impression; CSRI=Client Service Receipt Inventory; DES=Dissociative Experiences Scale; GAF=Global Assessment of Functioning; HADS=Hospital Anxiety & Depression Scale; HAM-A=Hamilton Anxiety Rating Scale; HAM-D=Hamilton Depression Rating Scale; IPQ=Illness Perception Questionnaire; PMDRS=Psychogenic Movement Disorder Rating Scale; QALY=quality adjusted life years; QoLIE=Quality of Life in Epilepsy; SF-36=Short Form Health Survey-36; WSAS=Work and Social Adjustment Scale

*extended PHQ-15 [S29]

Core symptoms

Clinical Global Impression-Improvement scale

Few studies reported data pertaining to the validity or reliability of the CGI-I scale in FND samples. In one study patient-rated CGI-I scores were significantly predicted by post-treatment change in Health of the Nation Outcomes Scale scores (HoNoS, p=0.033).[S30] However, another noted no significant associations between clinician-rated CGI-I and SF-36 or HADS scores,[S31] suggesting weak convergent validity with these outcome domains. Only one study examined reliability, noting moderate IRR between clinician-rated CGI-I and CGI-severity scores (kappa=0.65).[S10]

Some data suggested that the CGI-I scale is sensitive to change in this population. Post-treatment improvements were reported in most studies. The proportion of patients
reporting improvement after an intervention was 60-96% in 6/9 studies. [S9, S15, S30, S32-S34] In two studies, 30-48% of the active intervention groups reported improvements, [S10, S20] whereas in one study only average scores were reported. [S7] Average reported patient- and clinician-rated CGI-I scores were in the minimally-much improved range. [S7, S31, S33, S35] Significant treatment effects in patient- and clinician-rated CGI-I scores were observed, [43, S2, S19, S20] although not consistently. [42, S6, S10] Effect sizes varied from small to large. [43, S2, S10, S20] These findings suggest that the CGI-I scale has adequate responsiveness in FND patients, but more data are needed for different symptom types and treatment modalities.

Seizure frequency/freedom
There were no data available on reliability for seizure outcomes and few studies reported data relevant to validity in these FND samples. De Barros et al. noted significant correlations between post-treatment seizure frequency and HAM-D, HAM-A and alexithymia scores (p<0.05). [S36] Furthermore, Kuyk et al. observed a significant negative correlation between post-treatment seizure frequency and SF-36 energy-vitality scores (p<0.05). [S37] Seizure free patients showed significantly greater improvement on several SF-36 subscales (mental health, energy-vitality, pain), BDI, and STAI (anxiety) scores, relative to patients who were not seizure free (p<0.05).

Post-treatment decreases in seizure frequency or increases in seizure freedom were observed in a proportion of patients across all studies. A number of studies reported statistically significant treatment effects on seizure frequency [39, 40, 42-44, S2, S4, S36-S44] or seizure freedom. [38, S45] Effect sizes were generally small-medium. [40, 42, S2, S4] Future studies should standardise the methods of logging/comparing seizure outcomes to provide more comparable data.

Psychogenic Movement Disorder Rating Scale
Dreissen et al. reported adequate IRR for the PMDRS (average intraclass correlation (ICC)=0.76), [S10] which is lower than the original values presented by Hinson et al (0.87-0.89) [32] but both are in an acceptable range. Regarding validity, Taib et al. [S7] observed significant negative correlations between PMDRS total and SF-36 physical role scores (r = -0.77, p=0.0002), and between PMDRS total and SF-36 general health scores (r = -0.67, p=0.02). PMDRS total scores also correlated positively with CGI-severity (r=0.88, p=0.001).
Similarly, the original validation study noted a positive correlation between CGI and total PMDRS scores.[32] These relationships suggest good convergent validity. Seven out of 10 studies reported significant treatment effects for the PMDRS;[32, S5, S7, S32, S46-S48] and one noted a significant improvement in a placebo arm but not for the active intervention.[S8] Together, these findings suggest that the PMDRS shows adequate sensitivity to change in people with FMD.

Other physical symptoms
The two most common measures of additional physical symptoms were the PHQ-15 and the SCL-90 somatic symptoms scale. There were no data available regarding the reliability or validity of these measures in these FND intervention studies.

Patient Health Questionnaire-15
Five studies presented post-treatment data for the PHQ-15. Four studies reported significant reductions in post-treatment scores.[S5, S20, S30, S49] Williams et al.[22] also noted a decline in symptoms, but the statistical significance did not withstand correction for multiple testing (p=0.03). One study reported a medium effect size (d=0.53).[S30] Together, these findings suggest that the PHQ-15 shows good responsiveness across FND subgroups.

Symptom Checklist-90
Five studies reported outcomes on the SCL-90 somatic scale, with two observing significant improvements [S2, S40] and one reporting a large effect size.[S2] The responsiveness of this scale in FND samples requires further examination.

Psychological symptoms
The HADS, BDI (I or II) and BAI were common patient-rated outcome measures for anxiety and depression, and the HAM-D and HAM-A were often used as clinician-rated measures. There were no data regarding reliability for these measures in these FND samples.

Hospital Anxiety & Depression Scale
Conwill et al.[S31] reported no significant association between HADS and CGI-I (clinician) scores, suggesting poor convergent validity with core symptom change. Outcome data for
the HADS were provided in 12 studies; however, significant treatment effects were only reported in four (33%) and reported effect sizes were variable.[43, S30, S39, S44]

**Beck Depression Inventory & Beck Anxiety Inventory**

There were no data on the validity of the BDI/BAI in these FND samples. Nine studies reported outcomes for the BDI (I or II), with six (67%) reporting significant treatment effects.[39, S2, S19, S40, S43, S50] Large effect sizes were reported in two studies.[39, S2] Six studies provided outcome data for the BAI, with significant treatment effects observed in four.[32, S2, S5, S46] and a large effect size in one.[S2] One study reported a significant improvement in two treatment arms.[S6]

**Hamilton Anxiety Rating Scale & Hamilton Depression Rating Scale**

HAM-A and HAM-D scores positively correlated with post-treatment seizure frequency in one study.[S36] Demartini et al.[S32] found that HAM-A and HAM-D scores were significantly higher in FND patients relative to healthy controls at baseline, suggesting adequate known-groups validity.

Three of five studies reporting outcome data for the HAM-A reported significant treatment effects.[38, S36, S44] Two studies showed non-significant trends for improvement following treatment.[S8, S32] Thirteen studies reported post-treatment outcomes for HAM-D scores, six reporting significant effects.[32, S2, S5, S36, S44, S46] Vizcarra et al.[S8] noted a significant improvement in a placebo arm but not an intervention arm, whereas Kompoliti et al.[S6] noted significant improvements in two treatment arms. Effect sizes were moderate-large (d=0.71-1.8).[S2, S36]

**Life impact**

**Short Form Health Survey-36 & Short Form Health Survey-12**

The SF scales were the most consistently used of all measures in these studies (most often SF-36). There were no data available on their reliability in the FND samples, but three studies examined correlations with other relevant measures. Conwill et al.[S31] found no significant associations between SF-36 scores and CGI-I (clinician) ratings. However, Kuyk et al.[S37] noted significantly greater improvements on SF-36 domains (mental health, energy-vitality, pain) for seizure-free patients at follow-up. Williams et al.[22] observed a significant
positive correlation between post-treatment SF-36 mental health component scores and emotional processing improvements (p<0.008).

Significant treatment effects were observed on domains of the SF-36/SF-12 in 14/18 studies presenting outcome data.[22, S11, S15, S19, S20, S22, S31, S32, S34, S36, S37, S42, S49, S51] Effect sizes were generally moderate.[22, S15, S34, S36] Significant effects were most often observed for mental health (k=9), emotional role (k=4), general health (k=4), social function (k=4), and physical function (k=4). Several studies showed differences in the physical component (k=3), physical role (k=3) and energy/vitality (k=3) domains.

Quality of Life in Epilepsy-31 & Quality of Life in Epilepsy-10
No data on validity or reliability were available for the QoLIE scales in these functional seizure samples. However, post-treatment outcome data were available in seven studies. Four reported significant treatment effects [39, S2, S4, S40] and one reported a non-significant trend towards improvement.[S52] Effects sizes were moderate-large.[39, S2, S4]

Work and Social Adjustment Scale
The WSAS was included in 10 studies. There were no data on validity and reliability of the WSAS in the FND samples included. Of eight studies with outcome data, three reported significant treatment effects.[45, S34, S39] Reported effect sizes were small.[S15, S45] The measurement properties of the WSAS in FND require further examination.

Global Assessment of Functioning
In the five FND intervention studies providing data on the GAF, there were no details on its validity or reliability. Four studies, however, showed significant treatment effects.[32, S2, S40, S53] LaFrance et al.[S2] reported large effect sizes (d=1.2-1.8).

Health economics and cost-utility
Healthcare resource utilisation
A proportion of studies reported data on healthcare resource utilisation. The most common way to measure this was to obtain a frequency count of healthcare contacts (e.g., total healthcare contacts, emergency department, inpatient hospital days, outpatient contacts, mental health contacts), either by self-report or obtained from clinical records. No
data were available for validity and reliability and few significant differences were noted following treatment in these FND samples.

In patients with functional seizures, significant post-treatment reductions in emergency department visits and overall healthcare use [S2, S41] and greater probability of contact with a mental health professional [S3] were reported in a few studies. In patients with mixed FND symptoms, Aybek et al.[S51] observed reduced post-intervention medical follow-up and Hubschmid et al.[S19] reported fewer post-intervention inpatient hospital days. Greater consistency is needed in healthcare use measurement in future studies.

Quality adjusted life years (QALYs)
A minority of studies reported data on QALYs (k=3). Nielsen et al.[S15, S34] calculated QALY utility scores from the EQ-5D-5L, reporting post-treatment gains of 0.125 and 0.08. One study reported the average cost per QALY as £12,087.[S15] Reuber and colleagues reported QALY data derived from the SF-36, reporting post-treatment gains of 0.04 and an average cost per QALY of £5328.[S49] More data are needed on QALYs and their associated costs for different FND treatments.

Illness perceptions/attributions
Illness perceptions and attributions were measured often with the IPQ or revised versions. There was no evidence of the reliability or validity of the IPQ in these FND samples. Demartini et al. noted that IPQ-R scores at baseline were not predictive of patient-rated CGI-I outcomes (p=0.77).[S30]

All seven studies providing post-treatment data on the IPQ (or B-IPQ, IPQ-R) reported statistically significant post-treatment improvements. Some studies reported post-treatment reductions in composite scores.[22, S15, S45] Other studies reported significant improvements on individual items, including: beliefs about illness permanence (timeline, k=3), perceived negative consequences (k=2), and level of concern (k=2). Individual studies also reported significant differences in illness understanding, emotional representations, physical attributions, psychological attributions, and belief in possible cure/management.
Several studies explored illness beliefs with study-specific methods. In patients with functional seizures, belief that the seizures could be helped (OR=3.9, p=0.003), subjective control (OR=3.3, p=0.021), and an internal locus of control (OR=7.5, p<0.001) significantly predicted seizure freedom at follow-up.\[S54\] Significant post-treatment changes in beliefs relating to functional seizures have been noted, including perceived control, being bothered by the seizures, perceived impact, ability to avoid triggers, and perceived understanding.\[39, 45, S45\] Additional data are needed to explore the importance of these changes for patients’ outcomes.

**FND-COM consensus opinion**

Key points that emerged from the FND-COM group meetings and subsequent interchanges were as follows:

**General issues**

- Challenges for FND outcome measurement include the temporal variability of symptoms and the impact of attention, beliefs and expectations.
- Patient-rated outcome measures are important when assessing outcomes in this population.
- Discrepancies between objective and patient-rated outcomes may provide insights into the mechanisms underlying symptoms and treatment responses.

**Measuring FND symptom change**

- There are few validated outcome measures for FND symptoms across symptom types.
- There was some dissatisfaction with the PMDRS amongst the FND-COM members. Key limitations of this scale have been outlined elsewhere.\[33\]
- Of the clinician-rated scales for FMDs, the S-FMDRS was preferred by the FND-COM group due its ease of administration and lack of requirement for expertise in movement disorder phenomenology. However, this measure currently is not used widely, possibly due to time constraints, cost and the limitations of ‘snap-shot’ clinician-rated measures.
- Assessing the criterion validity of new FND-specific symptom measures is challenging due to a lack of existing ‘gold-standard(s)’.
• An individualised approach could be considered, whereby patients select the most troublesome symptoms and then use an individualised scale to assess change on these difficulties, or in which patient-specific goals are identified and progress towards them is subsequently monitored (e.g., PSYCHLOPS; Goal Attainment Scaling).[S55, S56]

Additional outcome domains
• Measures of the impact of FND (i.e., quality of life, disability, functioning, psychological distress) are important domains as they are relevant across all symptom types.
• Existing, generic outcome measures, known to be reliable and valid in related populations, can be used for adjunctive key outcome domains in FND (e.g., quality of life, additional physical symptoms, global functioning).
• Illness beliefs and attributions may be important mediators of treatment response and/or might represent a common domain of change across different treatments.

DISCUSSION
We aimed to identify FND-specific outcome measures, describe the outcome domains and measures most commonly included in previous FND intervention studies, integrate these findings with FND-COM group expert opinion and present preliminary recommendations for outcome measurement in future studies.

Existing FND-specific outcome measures
Only five FND-specific outcome measures were eligible: three clinician-rated scales[32-34] and two self-report measures.[35, 36] There were no measures specifically for functional limb weakness or sensory symptoms. Importantly, there is no single outcome measure suitable for use across all adult FND symptom types.

Of the identified scales, content validity was not established rigorously and the validation studies were limited by homogeneous or unrepresentative samples, cultural specificity and a lack of evidence of ecological validity. Data on responsiveness were not available for all scales.[34-36] Due to the limited evidence for satisfactory measurement properties of the scales identified,[28, 30] it is not possible to recommend their use as core outcome measures at present.
There is a clear absence of FND-specific outcome measures to capture the full spectrum of FND symptoms. It is therefore unclear whether any single measure could adequately capture all relevant domains for the FND population given its semiologic and symptomatic heterogeneity. Furthermore, it is possible that FND-specific outcome measures may be unnecessary and that existing measures used in other related disorders are valid and reliable for measuring outcomes in FND.

**Outcome domains and measures in previous FND intervention studies**

Outcome domains measured commonly in previous intervention studies included core FND symptoms, other physical symptoms, psychological symptoms, life impact (quality of life, disability, general functioning), and health economics or cost-utility (healthcare resource utilisation, QALYs). These domains and the associated measurement tools are discussed below.

**Core FND symptom change**

The CGI scales and patient-reported seizure frequency or freedom (functional seizures) were the most consistently used measures of symptom change. The main advantage of the CGI-I scale is that it can be used across the full range of FND symptoms, allowing for direct comparisons of treatments across diverse presentations. It is brief and simple to administer and can assess specific symptoms or global clinical status. However, there are scarce data on the validity and reliability of this scale in FND samples, and mixed findings regarding its responsiveness. Another limitation is the lack of evidence for interrater reliability of the CGI. Furthermore, the scale is ordinal in nature (i.e., scores are relative to baseline state only) and does not provide an absolute quantification of the utility of an intervention. There are data from other relevant patient populations suggesting acceptable measurement properties,[S57-S61] but future studies should examine further the properties of this scale in FND samples, including correlations between patient and clinician ratings. A modified version of the CGI for use in FND could also be considered, similarly to its use in other disorders.[S62, S63]

The assessment of seizure frequency and/or freedom was the most common outcome for studies involving functional seizures. However, there was variability in how these were
defined and a lack of data on their reliability and validity. Some preliminary evidence of convergent validity with other outcome domains was available. Importantly, improvements in seizure outcomes were observed consistently, with many studies reporting significant treatment effects. A standardised approach to operationalising seizure outcomes would be beneficial for future studies.\[S64\] It may be relevant to monitor duration/severity and specific seizure symptoms, as well as event frequency.

Clinician-rated scales were adopted most often for FMD. The PMDRS was used frequently and findings suggested some sound measurement properties. However, the face validity of the measure has not been examined sufficiently and doubts have been raised about its practical utility, along with other limitations.\[33\]

Other physical symptoms
Additional physical symptoms were often measured in previous studies. The FND-COM group agreed that these symptoms are important outcomes for FND patients, particularly pain and fatigue, which are prevalent and impactful. The two most common measures of additional physical symptoms (PHQ-15, SCL-90 somatic scale) lacked evidence of reliability and validity in studies of FND samples. Responsiveness was superior for the PHQ-15, this measure is brief and it has been validated across a wide range of physical and mental health diagnoses in various clinical and cultural settings.\[47, S65-S68\] The PHQ-15, therefore, is a potentially useful measure, but more data on its measurement properties are needed in FND. Extended versions of the PHQ-15 \[S29\] can also be considered in future research.

Psychological symptoms
Many studies included one or more measure of psychological symptoms, most often depression and/or anxiety, measured by the HADS or BDI and BAI (patient-rated) or HAM-A and HAM-D (clinician-rated).

There are several advantages of using the HADS, including its brevity, combined anxiety and depression subscales in a single measure, and the omission of physical manifestations, reducing the likelihood of confounding physical with psychological symptoms. The measurement properties of the HADS in FND samples are not well described and more
data are needed. However, the HADS has shown good measurement properties across other physical and mental health diagnoses and cross-culturally.[S69-S74]

Evidence for the reliability and validity of the BDI (BDI-II) and BAI in FND was lacking in the FND intervention studies reviewed. Responsiveness was stronger for these measures, but interpretation is potentially hindered by the inclusion of physical symptoms in these scales (e.g., fatigue, sleep disturbance, tremor). Nevertheless, both the BAI and BDI/BDI-II have also been validated in a range of clinical and non-clinical populations, and across cultures.[S75-S79] The HAM-A and HAM-D seem to be the most useful clinician-rated measures of psychological symptoms. Although reliability and validity have not been rigorously examined in FND samples, these scales show preliminary evidence of adequate responsiveness.

Life impact
The most common measure of life impact was the SF-36. This measure has the advantage of assessing patients’ subjective perceptions of overall health status, aspects of disability, physical and mental health in a single measure, and can also be used for the derivation of QALYs. A key benefit of the SF-36 for use in FND is its multidimensional nature; it is possible to examine outcomes on eight specific subscales, depending on the goals and modality of a given treatment. Again, there was a paucity of reliability and validity data in FND samples, but there is considerable evidence for responsiveness, with most studies reporting significant treatment effects on at least one SF-36 domain. The SF-36 has also been well-validated across clinical populations and cultures.[S80-S82] The QoLIE scales serve a similar purpose in functional seizures but more data are needed on the measurement properties in FND samples.

Additional measures of life impact include measures of general (social, occupational) functioning. The WSAS is often used to capture patient-reported general functioning and the GAF for clinician-ratings. No evidence is available for the reliability or validity of either scale in FND samples. The responsiveness of the GAF appeared slightly stronger in the studies presented here.
Health economics and cost-utility
Health economic data were primarily derived from healthcare resource utilisation frequency, with the CSRI or study-specific questions about healthcare contacts being the most common methods. The CSRI was developed in the UK, so it requires adaptation to local regions and is a relatively lengthy measure to administer; therefore, it is unlikely to be appropriate for widespread international use. Instead, specific questions about healthcare contacts (e.g., emergency department or outpatient visits, inpatient hospital admissions, inpatient days) appear to be more generalisable methods. The EQ-5D(5L) and SF-36 allow the derivation of QALYs and associated costs. [S83, S84] Future research is needed to compare the relative cost-utility of treatment modalities for different subgroups of FND patients.

Illness perceptions/symptom attributions
Illness perceptions/beliefs were noted by the FND-COM group as also important to measure in FND treatment studies, as they might mediate change across different treatment modalities and symptom types. Of note, 100% of studies including a version of the IPQ noted significant treatment effects on composite IPQ scores or specific items. The original IPQ is relatively lengthy but the B-IPQ or IPQ-R could be adopted (or modified) to better assess FND-relevant cognitions (e.g., acceptance/understanding of the diagnosis, beliefs about causation, subjective control).

FND-COM recommendations for outcome measurement in FND
In the absence of rigorously validated, widely endorsed FND-specific outcome measures, we recommend an interim approach involving the assessment of core outcome domains with existing patient-rated measures that are valid, reliable and sensitive to change in FND or other relevant populations. The core domains and recommended measures are detailed in Table 4, alongside additional supplementary patient- or clinician-rated measures. We recommend that these measures (or a subset) are assessed in future intervention research in adult FND populations.

There are similarities between the domains identified here and those described in recommendations for other related disorders (e.g., chronic pain, fibromyalgia, complex
regional pain syndrome, somatic symptom disorders). The outcome domains and measures recommended here could be supplemented with additional tools depending on the specific intervention and patient characteristics within individual studies. We also acknowledge that adaptations to these recommendations might be necessary due to cultural/context-specific factors. Furthermore, cost considerations may affect the use of the recommended measures, as some are licensed.

Table 4: Preliminary recommendations for outcome measurement in FND

<table>
<thead>
<tr>
<th>Outcome domain</th>
<th>Recommended measures</th>
<th>Supplementary / alternative measures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Core FND symptoms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• CGI-I (patient +/- clinician +/- carer)</td>
<td>• Seizure frequency; prospective daily seizure log (for seizures)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• S-FMDRS or PMDRS (for FMD)</td>
</tr>
<tr>
<td><strong>Other physical symptoms</strong></td>
<td>• PHQ-15</td>
<td>• Extended PHQ-15</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• SCL-90</td>
</tr>
<tr>
<td><strong>Psychological symptoms</strong></td>
<td>• HADS or BDI/BDI-II + BAI</td>
<td>• HAM-D + HAM-A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Life impact</strong></td>
<td><strong>Quality of Life</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• SF-36 and/or General (social/occupational) functioning</td>
<td>• QoLIE-31/10 (for seizures)</td>
</tr>
<tr>
<td></td>
<td>• WSAS</td>
<td>• GAF</td>
</tr>
<tr>
<td><strong>Health economics/cost utility</strong></td>
<td>Healthcare resource utilisation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Healthcare contacts (total, inpatient admissions, inpatient days, ED/outpatient visits)</td>
<td>• CSRI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Scale validated for QALY conversion (EQ-5D-5L or SF-36)</td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td>AEs, SAEs, mortality</td>
<td></td>
</tr>
</tbody>
</table>

Key: AEs=adverse events; BAI=Beck Anxiety Inventory; BDI=Beck Depression inventory; CGI-I=Clinical Global Impression – Improvement; CSRI=Client Service Receipt Inventory; ED=emergency department; FMD=functional movement disorder; FND=functional neurological disorder; GAF=Global Assessment of Functioning; HADS=Hospital Anxiety 7 Depression Scale; HAM-A=Hamilton Rating Scale for Anxiety; HAM-D=Hamilton Rating Scale for Depression; PHQ=Patient Health Questionnaire; PMDRS=Psychogenic Movement Disorder Rating Scale; QALY=quality adjusted life years; QoLIE-31/10=Quality of Life in Epilepsy-31/10; S-FMDRS=Simplified Functional Movement Disorder Rating Scale; SAEs=serious adverse events; SCL=Symptom Checklist; SF-36=Short Form Health Survey-36; WSAS=Work & Social Adjustment Scale

Limitations

This article had some limitations. Articles not written in English were excluded. Future research on outcome measurement in FND should aim to examine cultural variation in practices, and outcome measures should be validated across cultural contexts. The focus of this article was on identifying and evaluating outcome measures specifically, so we did not conduct a quality appraisal of the methods used to assess the effectiveness and efficacy of
the interventions, nor did we evaluate the quality and significance of the outcome data in relation to the treatment modalities tested.

**Future directions**
This review highlighted several directions for future research and development. Firstly, FND experts should convene to discuss further the need for new FND-specific outcome measures for use across all symptom types and additional tools for individual symptom types. Additional measures could include patient-rated, clinician-rated, caregiver-rated and/or objective measures. If deemed appropriate, the development and validation of such scales should be prioritised. Consideration of content and face validity should be given during the design and development of any new scales. Secondly, future FND intervention studies should aim to present data on the measurement properties of the outcome measures included (where possible), to strengthen the evidence-base for the use of specific measures in FND. Outcome measures that are used frequently (e.g., seizure frequency, SF-36, PMDRS) should undergo more extensive psychometric evaluation, where feasible, in larger samples of FND patients, ideally across different cultures.

Future research may explore additional avenues for outcome measurement in FND, such as the use of objective/performance-based measures (e.g., actigraphy, 5-metre walk test), or personalised symptom rating or goal attainment scales. Discrepancies between patient-rated and objective/clinician-rated measures may provide important insights into mechanisms underlying symptoms or therapeutic change. Additional psychological domains that could be relevant for future investigation include illness beliefs, psychological dissociation (e.g., depersonalisation, derealisation) and aspects of emotional processing (e.g., stress reactivity, alexithymia). It will also be important to explore which outcome domains and measures are most relevant for additional functional neurological symptoms not covered in this review, such as cognitive (e.g., consciousness, memory), speech and swallowing symptoms.

An important direction for further research is to examine the perspectives of patients, carers and other relevant stakeholders on outcome measurement in FND, particularly exploring views on the relative merits of subjective and objective measures. Additional work is needed to develop recommendations for outcome measurement in children with FND,
given that many of the recommended measures may not be validated or relevant for younger patients.

**CONCLUSIONS**

There is a need for greater consistency in outcome measurement in FND research. At present, we recommend an interim set of outcome measures to routinely assess core outcome domains including: core FND symptom change, other physical and psychological symptoms, life impact, health economics/cost-utility, and adverse events. These recommendations could be supplemented with additional measures as appropriate to individual studies. Further research is needed to provide more extensive psychometric evaluation of outcome measures for FND and to explore the views of patients, carers and other stakeholders on optimising outcome measurement in this disorder.
**Contributors**

TRN and SPick formulated the idea for the review and TRN, SPick and AJC planned the overall structure, with input from the FND-COM group. SPick conducted the literature reviews, extracted the data, prepared the tables/figures, and wrote the manuscript (including revised versions). TRN contributed to the tables in Supplementary Files 3 and 4. ABW, TRN, RCK and SPopkirov independently screened a subset of titles/abstracts during the literature review. All other authors contributed to the FND-COM meetings or discussions in person, by email or teleconference. All authors reviewed the manuscript for intellectual content and/or suggested revisions.

**Funding**

AJE has received grant support from the NIH and the Michael J Fox Foundation.

LHG reports salary support from the UK National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King’s College London. TRN and SPick are also funded by a NIHR clinician scientist fellowship. GN also receives funding from the NIHR. RCK received a NIHR Academic Clinical Fellowship in General Adult Psychiatry and a Royal College of Psychiatrists Gosling Fellowship. She also receives PhD funding from King’s College London and a King’s IoPPN Clinician Investigator Scholarship.

MH is supported by the National Institute of Neurological Disorders and Stroke Intramural Programme (National Institutes of Health, US).

TS has received support from Ministry of Health of the Czech Republic, grant AZV ČR 16-29651.

**Disclaimer**

The views expressed in this publication are those of the authors and not necessarily those of the NHS (UK), the NIHR (UK), the Department of Health and Social Care (UK) or the NIH/NINDS (US).
**Competing interests**

AAP reports honoraria from Cobel Daruo, Sanofi, and RaymandRad; Royalty from Oxford University Press (book publication).

AJC reports independent expert testimony work for personal injury and medical negligence claims, is a paid associate editor of JNNP and runs a free non-profit self-help website, www.headinjursymptoms.org.

AJE has received personal compensation as a consultant/scientific advisory board member for Abbvie, Adamas, Acadia, Acorda, Neuroderm, Impax/Amneal, Sunovion, Lundbeck, Osmotica Pharmaceutical, and USWorldMeds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer; and honoraria from USWorldMeds, Lundbeck, Acadia, Sunovion, the American Academy of Neurology, and the Movement Disorders Society.

BM has received honoraria from The Cleveland Clinic and runs a free non-profit self-help website www.fndhope.org.

DLP has received honoraria from the American Academy of Neurology, Movement Disorder Society and Harvard Medical School.

JS reports independent expert testimony work for personal injury and medical negligence claims and receives royalties from UpToDate for articles on functional neurological disorder and runs a free non-profit self-help website, www.neurosymptoms.org.

KL has received honoraria from the American Academy of Neurology and the Movement Disorder Society.

MH may accrue revenue on US Patent for an Immunotoxin (MAB-Ricin) for the treatment of focal movement disorders and for a Coil for Magnetic Stimulation and methods for using the same (H-coil); in relation to the latter, he has received license fee payments from the NIH (from Brainsway). He is on the Medical Advisory Boards of CALA Health, Brainsway, and Cadent. He is on the Editorial Board of approximately 15 journals and receives royalties
and/or honoraria from publishing from Cambridge University Press, Oxford University Press, Springer, and Elsevier. Grant research funds have come from Merz for treatment studies of focal hand dystonia, Allergan for studies of methods to inject botulinum toxins, Medtronic, Inc. for a study of DBS for dystonia, and CALA Health for studies of a device to suppress tremor.

MJE reports independent expert testimony work for personal injury and medical negligence claims and receives royalties from the Oxford Specialist Handbook of Parkinson’s Disease and Other Movement Disorders. He has received honoraria from Merz Pharma and Boeringher Ingleheim.

WCL has served on the editorial boards of Epilepsia, Epilepsy & Behavior; Journal of Neurology, Neurosurgery and Psychiatry; and Journal of Neuropsychiatry and Clinical Neurosciences; receives editor’s royalties from the publication of Gates and Rowan’s Nonepileptic Seizures, 3rd ed. (Cambridge University Press, 2010) and 4th ed. (2018); author’s royalties for Taking Control of Your Seizures: Workbook and Therapist Guide (Oxford University Press, 2015); has received research support from the Department of Defense (DoD W81XWH-17-0169), NIH (NINDS 5K23NS45902 [PI]), Providence VAMC, Center for Neurorestoration and Neurorehabilitation, Rhode Island Hospital, the American Epilepsy Society (AES), the Epilepsy Foundation (EF), Brown University and the Siravo Foundation; serves on the Epilepsy Foundation New England Professional Advisory Board; received honoraria for the American Academy of Neurology Meeting Annual Course; served as a clinic development consultant at University of Colorado Denver, Cleveland Clinic, Spectrum Health, Emory University and Oregon Health Sciences University; and provided medicolegal expert testimony.

**Patient consent**

Not required.

**Provenance and peer-review**

Not commissioned; externally peer reviewed.
REFERENCES


[References S1-S89 are available in Supplementary File 7]